连续性肾脏替代疗法治疗重症急性肾衰竭的临床效果观察

Clinical effect observation of continuous renal replacement therapy in the treatment of patients with severe acute renal failure

目的 探讨连续性肾脏替代疗法对重症急性肾衰竭患者的临床治疗效果。方法 将70例重症急性肾衰竭患者分为对照组与治疗组,每组35例。对照组采用间歇性血液透析治疗,治疗组采用连续性肾脏替代治疗,比较2组临床疗效、治疗前后肾功能指标改善情况、并发症发生情况及术后1年生存率、病死率。结果 治疗组患者的治疗总有效率为94.29%,显著高于对照组的57.14%(P<0.05)。对照组患者的并发症发生率为40.00%,显著高于治疗组的5.71%(P<0.05)。治疗后,治疗组的血尿素氮(BUN)、血清肌酐(Scr)高于对照组,内生肌酐清除率(Ccr)低于对照组,差异有统计学意义(P<0.05)。在治疗1年后,治疗组生存率、病死率显著优于对照组(P<0.05)。结论 连续性肾脏替代疗法能够显著提高重症急性肾衰竭患者的临床治疗效果和存活率,改善肾功能,降低并发症发生率和病死率。

Objective To investigate the clinical effect of continuous renal replacement therapy on the treatment of patients with severe acute renal failure.Methods Totally 70 patients with severe acute renal failure were divided into control group and treatment group,with 35 cases in each group.The control group was treated with intermittent hemodialysis,while the treatment group was treated with continuous renal replacement therapy.The clinical efficacy,improvement of renal function before and after treatment,complications,1-year survival rate and mortality after surgery were compared between the two groups.Results The total effective rate was 94.29%in the treatment group,which was significantly higher than 57.14%in the control group(P<0.05).The incidence rate of complications in the control group was 40.00%,which was significantly higher than 5.71%in the treatment group(P<0.05).After treatment,blood urea nitrogen(BUN)and serum creatinine(Scr)in the treatment group were significantly higher than those in the control group,and endogenous creatinine clearance(Ccr)was significantly lower than that in the control group(P<0.05).After one year of treatment,the survival rate and mortality of the treatment group were significantly better than those of the control group(P<0.05).Conclusion Continuous renal replacement therapy can significantly improve the clinical efficacy and survival rate of patients with severe acute renal failure,improve renal function,and reduce the incidence rate of complications and mortality.